ATR - AptarGroup, Inc.
State of Alaska Department of Revenue raised its holdings in AptarGroup, Inc. (NYSE: ATR) by 53.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,622 shares of the industrial products company's stock after purchasing an additional 4,773 shares during the quarter. State
Shares of AptarGroup, Inc. (NYSE: ATR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year
AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.
Tidal Investments LLC lowered its position in AptarGroup, Inc. (NYSE: ATR) by 24.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,987 shares of the industrial products company's stock after selling 5,814 shares during the quarter. Tidal Investments LLC's holdings
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,200 shares of the industrial products company's stock, valued at approximately $526,000. Other institutional investors have also recently bought and
AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world evidence planned for a new U.S. FDA De Novo submission for DrugSorb-ATR® Recent FDA Pre-Submission meetings provided constructive feedback on potential U.S. regulatory pathways for DrugSorb-ATR for separate applications for ticagrelor and direct oral anticoagulant removal in urgent cardiac surgery PRINCETON, N.J., Sept. 2, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery on the blood thinner, ticagrelor (Brilinta®/Brilique®, AstraZeneca).
Callan Family Office LLC acquired a new stake in AptarGroup, Inc. (NYSE: ATR) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,429 shares of the industrial products company's stock, valued at approximately $1,181,000. A number of other
Deutsche Bank AG bought a new stake in AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 119,035 shares of the industrial products company's stock, valued at approximately $14,903,000. Deutsche Bank AG owned approximately 0.19% of
Aurora Investment Counsel acquired a new stake in shares of AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,785 shares of the industrial products company's stock, valued at approximately $1,475,000. Other hedge funds have
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS). "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis — Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.
Bank of America Corp DE boosted its position in AptarGroup, Inc. (NYSE: ATR) by 7.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,718 shares of the industrial products company's stock after buying an additional 32,420 shares during the
ATR tops Q2 earnings and revenue estimates as pharma and beverage growth lift quarterly revenues above $1B for the first time despite margin pressure.
California State Teachers Retirement System grew its position in shares of AptarGroup, Inc. (NYSE: ATR) by 24.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,227 shares of the industrial products company's stock after buying an additional 15,158
AptarGroup, Inc. (NYSE: ATR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month
Review AptarGroup's (ATR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
AptarGroup, Inc. (ATR) Q2 2026 Earnings Call Transcript